Different individuals with the same cancer can respond differently to the same therapy.
Detecting these genomic alterations yields a more complete picture of the cancer.
With this information, an oncologist can personalize treatment and improve outcomes.
Genomic alterations can be identified through genomic sequencing of the tumor using the StrandAdvantage Test.
StrandAdvantage can test for the most common solid tumors.
For example breast, colon and lung cancers but also other rarer cancer types.
Any individual diagnosed with a solid tumor.